Hospital de Gran Canaria Dr. Negrin -ko ikertzaileekin lankidetzan egindako argitalpenak (11)

2023

  1. Disease activity in patients with rheumatoid arthritis increases serum levels of apolipoprotein C-III

    Clinical and experimental rheumatology, Vol. 41, Núm. 1, pp. 67-73

2022

  1. Amylin serum levels are upregulated in patients with systemic lupus erythematosus

    Clinical and Experimental Rheumatology, Vol. 40, Núm. 7, pp. 1378-1384

  2. Apolipoprotein C-III is linked to the insulin resistance and beta-cell dysfunction that are present in rheumatoid arthritis

    Arthritis Research and Therapy, Vol. 24, Núm. 1

  3. Key Molecules of Triglycerides Pathway Metabolism Are Disturbed in Patients With Systemic Lupus Erythematosus

    Frontiers in Immunology, Vol. 13

  4. The angiopoietin-like protein 4, apolipoprotein C3, and lipoprotein lipase axis is disrupted in patients with rheumatoid arthritis

    Arthritis Research and Therapy, Vol. 24, Núm. 1

2021

  1. Differences in Capacity of High-Density Lipoprotein Cholesterol Efflux Between Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis

    Arthritis Care and Research, Vol. 73, Núm. 11, pp. 1590-1596

  2. Higher prevalence and degree of insulin resistance in patients with rheumatoid arthritis than in patients with systemic lupus erythematosus

    Journal of Rheumatology, Vol. 48, Núm. 3

  3. Proprotein convertase subtilisin/kexin type 9 in the dyslipidaemia of patients with axial spondyloarthritis is related to disease activity

    Rheumatology (Oxford, England), Vol. 60, Núm. 5, pp. 2296-2306

2020

  1. Comparable effects of traditional cardiovascular risk factors on subclinical atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis

    Clinical and Experimental Rheumatology, Vol. 38, Núm. 5, pp. 917-924

  2. Impaired HDL cholesterol efflux capacity in systemic lupus erythematosus patients is related to subclinical carotid atherosclerosis

    Rheumatology (Oxford, England), Vol. 59, Núm. 10, pp. 2847-2856

  3. Proprotein convertase subtilisin/kexin type 9 is related to disease activity and damage in patients with systemic erythematosus lupus

    Therapeutic Advances in Musculoskeletal Disease, Vol. 12